postoperative pain measured by this score.
intrathecaم Ketamine, Morphine and Both for Lower Abdominal Cancer Surgery Pain
Brief Summary
this study investigates the analgesic efficacy and other possible effects of ketamine, morphine, and both together when administered intrathecally for control of postoperative pain following lower abdominal cancer surgeries.
Intervention / Treatment
-
intrathecal morphine (DRUG)patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
-
intrathecal ketamine (DRUG)patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
-
intrathecal morphine + ketamine (DRUG)patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
Condition or Disease
- Postoperative Pain
Phase
Study Design
Study type: | INTERVENTIONAL |
---|---|
Status: | Completed |
Study results: | No Results Available |
Age: | 30 Years to 50 Years |
Enrollment: | 90 (ACTUAL) |
Funded by: | Other |
Allocation: | Randomized |
Primary Purpose: | Treatment |
MaskingTRIPLE:
|
Clinical Trial Dates
Start date: | Oct 01, 2015 | |
---|---|---|
Primary Completion: | Feb 01, 2016 | ACTUAL |
Completion Date: | Apr 01, 2016 | ACTUAL |
Study First Posted: | Apr 04, 2016 | ESTIMATED |
Results First Posted: | Aug 31, 2020 | |
Last Updated: | Jan 25, 2017 |
Sponsors / Collaborators
Lead Sponsor:
Assiut University
Responsible Party:
N/A
Participant Groups
-
patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine in 1 ml volume intrathecally.
-
patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
-
patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 30 |
Maximum Age: | 50 |
Age Groups: | Adult |
Healthy Volunteers: | Yes |
Inclusion Criteria:
* American Society of Anesthesia (ASA) I-III patients.
* aged 30-50 years.
* scheduled for major abdominal cancer surgery.
Exclusion Criteria:
* Patients with a known allergy to the study drugs.
* significant cardiac, respiratory, renal or hepatic disease.
* coagulation disorders.
* infection at or near the site of intrathecal injection.
* drug or alcohol abuse.
* BMI \> 30 kg/m2.
* psychiatric illnesses that may interfere with perception and assessment of pain.
* American Society of Anesthesia (ASA) I-III patients.
* aged 30-50 years.
* scheduled for major abdominal cancer surgery.
Exclusion Criteria:
* Patients with a known allergy to the study drugs.
* significant cardiac, respiratory, renal or hepatic disease.
* coagulation disorders.
* infection at or near the site of intrathecal injection.
* drug or alcohol abuse.
* BMI \> 30 kg/m2.
* psychiatric illnesses that may interfere with perception and assessment of pain.
Primary Outcomes
-
-
the time passed till the first request of rescue analgesia by the patients
-
the total amount of rescue analgesic drug used allover follow up period
Secondary Outcomes
-
the type and rate of incidence of side effects during the follow up period
More Details
NCT Number: | NCT02726828 |
---|---|
Other IDs: | 165 |
Study URL: | https://clinicaltrials.gov/study/NCT02726828 |
Last updated: Sep 29, 2023